ECM
FPRX

Endurant Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Endurant Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-421,398
Closed -$1.98M – 80
2020
Q3 		$1.98M Buy
421,398
+184,224
+78% +$936K 0.59% 45
2020
Q2 		$1.45M Buy
+237,174
New +$977K 0.08% 45

Other funds holding FPRX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Endurant Capital Management's FPRX Position: Q4 2020 in Review

Endurant Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2020, closing a stake of 421,398 shares — an estimated $1.98M sold.

Endurant Capital Management first reported a position in FPRX in Q2 2020 and held it in 2 quarters. The position peaked at $1.98M in Q3 2020. 125 funds tracked by Wall St. Rank hold FPRX as of Q4 2020.

  • Endurant Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Endurant Capital Management sold 421,398 Five Prime Therapeutics, Inc. shares in Q4 2020, an estimated $1.98M.
  • Endurant Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q2 2020 and held it in 2 quarters.
  • Endurant Capital Management's Five Prime Therapeutics, Inc. position peaked at $1.98M in Q3 2020.
  • 125 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2020.

Based on Endurant Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.